ArriVent BioPharma, Inc. AVBP
13.64 USD +1.41 (+11.53%)
At closeNov 6, 2026, 4:05 PM EST
13.64 0.00 0.00%
After hours · Nov 6, 4:05 PM ET
12.00 Day range 13.88
12.23 52-week range 34.74
- YTD
- -32.21%
- 1 year
- -25.83%
Financial health
Altman Z-Score
12.45 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
C+2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 2
Valuation
P/E -4.7×
FY 2021 5y median -9.2× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B 2.5×
FY 2021 5y median 3.3× FY 2025
P/FCF -4.8×
FY 2021 5y median -11.4× FY 2025
EV/EBITDA -4.4×
FY 2021 5y median -4.4× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -20.8%
FY 2021 5y median -8.7% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE -54.1%
FY 2021 5y median -45.8% FY 2025
ROIC -57.8%
FY 2021 5y median -36.6% FY 2025
ROA -49.9%
FY 2021 5y median -42.5% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -88.2%
FY 2021 FY 2025
EPS (diluted) -68.8%
FY 2021 FY 2025
Free Cash Flow -128.7%
FY 2021 FY 2025
Financial Health
Current Ratio 12.8×
FY 2021 5y median 13.8× FY 2025
Quick Ratio 12.8×
FY 2021 5y median 13.8× FY 2025
Debt / Equity 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA 0.3×
FY 2021 5y median 0.7× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31